EpiBiologics
San Mateo, CA · Biotechnology · 43 employees
EpiBiologics is advancing bispecific antibodies that selectively degrade membrane and soluble proteins, including GPCRs. Our EpiTAC platform leverages a novel atlas of tissue-selective degrader receptors to drive deep and durable efficacy. The company was founded in 2022 based on pioneering work from Dr. Jim Wells at UCSF. Headquartered in the SF Bay Area, EpiBiologics is backed by leading healthc
Funding history
- Series B — $107.0M — Jan 2026
- Venture - Series Unknown — $73.1M — Apr 2024
- Series A — Undisclosed — Jul 2023
- Venture - Series Unknown — $73.1M — Apr 2023
Recent signals
- Jan 08, 2026: Raised $107.0M in Series B
- Apr 25, 2024: Raised $73.1M in Venture - Series Unknown
- Jul 20, 2023: Raised funding in Series A
- Jul 20, 2023: EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million
- Apr 28, 2023: Raised $73.1M in Venture - Series Unknown
See plans & pricing → Track EpiBiologics’s funding, hiring, and signals — with verified contacts — on Fundz.